NEW DELHI, July 10: Natco Pharma on Friday said its Canadian subsidiary has entered into a settlement agreement with biopharmaceutical firm Celgene (part of Bristol-Myers Squibb) for Lenalidomide capsules.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells.
“Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada,” the company said in a regulatory filing.
The terms of the agreement are confidential as per the agreement, the company added.
(PTI)
Follow our WhatsApp channel
